Disease characterization using LQTS-specific induced pluripotent stem cells
The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
AIMS: Long QT syndrome (LQTS) is an inheritable and life-threatening disease; however, it is often difficult to determine disease characteristics in sporadic cases with novel mutations, and more precise analysis is necessary for the successful development of evidence-based clinical therapies. This study thus sought to better characterize ion channel cardiac disorders using induced pluripotent stem cells (iPSCs). METHODS AND RESULTS: We reprogrammed somatic cells from a patient with sporadic LQTS and from controls, and differentiated them into cardiomyocytes through embryoid body (EB) formation. Electrophysiological analysis of the LQTS-iPSC-derived EBs using a multi-electrode array (MEA) system revealed a markedly prolonged field potential duration (FPD). The IKr blocker E4031 significantly prolonged FPD in control- and LQTS-iPSC-derived EBs and induced frequent severe arrhythmia only in LQTS-iPSC-derived EBs. The IKs blocker chromanol 293B did not prolong FPD in the LQTS-iPSC-derived EBs, but significantly prolonged FPD in the control EBs, suggesting the involvement of IKs disturbance in the patient. Patch-clamp analysis and immunostaining confirmed a dominant-negative role for 1893delC in IKs channels due to a trafficking deficiency in iPSC-derived cardiomyocytes and human embryonic kidney (HEK) cells. CONCLUSIONS: This study demonstrated that iPSCs could be useful to characterize LQTS disease as well as drug responses in the LQTS patient with a novel mutation. Such analyses may in turn lead to future progress in personalized medicine.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Various cell models built with iPSC derivatives have been shown to resemble in vivo or primary cell counterparts at transcriptional, cellular, and functional levels whilst leaving little interference to the genetic content [4,5,6,7].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [6]
In the citing paper
“Previous studies using iPSC-derived cardiomyocytes from type-1 LQTS patients revealed that the mutation in KCNQ1 caused potassium ion channel dysfunction resulting in sarcolemmal deficiency [5,6].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [6]
In the citing paper
“Models built with iPSC derivatives also demonstrate functional and phenotypic traits comparable to their human in vivo parallel [4,5,6].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [6]
Citations
Cites
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007) · Science · doi:10.1126/science.1151526 · Cited by 10,310 · cited 1×
“Human-induced pluripotent stem cells (hiPSCs) have become a promising tool for analysing human genetic diseases.(8,9) Many studies have already shown that apparent cellular phenotypes of familial genetic disorders are recapitulated by disease-specific iPSC-derived cells in vitro.”
BackgroundZipes, D. P., & Wellens, H. J. J. (1998) · Circulation · doi:10.1161/01.cir.98.21.2334 · Cited by 2,744
Disease-Specific Induced Pluripotent Stem Cells.
Park, I.-H., Arora, N., Huo, H., Maherali, N., Ahfeldt, T., Shimamura, A., Lensch, M. W., Cowan, C., Hochedlinger, K., & Daley, G. Q. (2008) · Cell · doi:10.1016/j.cell.2008.07.041 · Cited by 2,196
Sudden Death Due to Cardiac Arrhythmias
Huikuri, H. V., Castellanos, A., & Myerburg, R. J. (2001) · New England Journal of Medicine · doi:10.1056/nejmra000650 · Cited by 1,466
Patient-Specific Induced Pluripotent Stem-Cell Models for Long-QT Syndrome
Moretti, A., Bellin, M., Welling, A., Jung, C. B., Lam, J. T., Bott-Flügel, L., Dorn, T., Goedel, A., Höhnke, C., Hofmann, F., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908679 · Cited by 1,251 · cited 1×
“However, most patients for generating iPSCs in previous reports were already diagnosed with responsible genes and/or had familial history.(10) –13,31,32 We showed here that iPSCs can recapitulate the phenotype of a sporadic patient with LQTS type1.”
BackgroundZipes, D. P., Camm, A. J., Borggrefe, M., Buxton, A. E., Chaitman, B., Fromer, M., Gregoratos, G., Klein, G., Moss, A. J., Myerburg, R. J., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.178233 · Cited by 1,080
Modelling the long QT syndrome with induced pluripotent stem cells
Itzhaki, I., Maizels, L., Huber, I., Zwi-Dantsis, L., Caspi, O., Winterstern, A., Feldman, O., Gepstein, A., Arbel, G., Hammerman, H., et al. (2011) · Nature · doi:10.1038/nature09747 · Cited by 1,049
Low Penetrance in the Long-QT Syndrome: Clinical Impact
Priori, S. G., Napolitano, C., & Schwartz, P. J. (1999) · Circulation · doi:10.1161/01.cir.99.4.529 · Cited by 804
Soldner, F., Laganière, J., Cheng, A. W., Hockemeyer, D., Gao, Q., Alagappan, R., Khurana, V., Golbe, L. I., Myers, R. H., Lindquist, S., et al. (2011) · Cell · doi:10.1016/j.cell.2011.06.019 · Cited by 728
Cited by
Karakikes, I., Ameen, M., Termglinchan, V., & Wu, J. C. (2015) · Circulation Research · doi:10.1161/circresaha.117.305365 · Cited by 478
Induced pluripotent stem cells: the new patient?
Bellin, M., Marchetto, M. C., Gage, F. H., & Mummery, C. L. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3448 · Cited by 431
Induced Pluripotent Stem Cells and Their Use in Human Models of Disease and Development
Karagiannis, P., Takahashi, K., Saito, M., Yoshida, Y., Okita, K., Watanabe, A., Inoue, H., Yamashita, J. K., Todani, M., Nakagawa, M., et al. (2019) · Physiological Reviews · doi:10.1152/physrev.00039.2017 · Cited by 368
Denning, C., Borgdorff, V., Crutchley, J., Firth, K. S. A., George, V., Kalra, S., Kondrashov, A., Hoang, M. D., Mosqueira, D., Patel, A., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.10.014 · Cited by 293
“For the heart, side effects can damage the structural integrity and survival of cardiomyocytes (CMs), as is the case with the anti-inflammatory drug, Vioxx [8], and many anti-cancer drugs, such as doxorubicin [9].”
BackgroundTranslation of Human-Induced Pluripotent Stem Cells
Sayed, N., Liu, C., & Wu, J. C. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.01.083 · Cited by 279
Induced Pluripotent Stem Cells 10 Years Later: For Cardiac Applications
Yoshida, Y., & Yamanaka, S. (2017) · Circulation Research · doi:10.1161/circresaha.117.311080 · Cited by 264
Investigating human disease using stem cell models
Sterneckert, J. L., Reinhardt, P., & Schöler, H. R. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3764 · Cited by 249
Musunuru, K., Sheikh, F., Gupta, R. M., Houser, S. R., Maher, K. O., Milan, D. J., Terzic, A., & Wu, J. C. (2018) · Circulation: Genomic and Precision Medicine · doi:10.1161/hcg.0000000000000043 · Cited by 229
Karakikes, I., Stillitano, F., Nonnenmacher, M., Tzimas, C., Sanoudou, D., Termglinchan, V., Kong, C.-W., Rushing, S., Hansen, J., Ceholski, D., et al. (2015) · Nature Communications · doi:10.1038/ncomms7955 · Cited by 196
“A deletion of amino acid arginine 14 in the coding region of the PLN gene (R14del) was first discovered in a large Greek family with hereditary DCM 5 and DCM patients heterozygous for the R14del mutation exhibit left ventricular dilation, contractile dysfunction and episodic ventricular arrhythmias,…”
Bellin, M., Casini, S., Davis, R. P., D'Aniello, C., Haas, J., Ward-van Oostwaard, D., Tertoolen, L. G. J., Jung, C. B., Elliott, D. A., Welling, A., et al. (2013) · The EMBO Journal · doi:10.1038/emboj.2013.240 · Cited by 196
“LQTS was one of the first cardiac diseases recapitulated using hiPSCs as a model (Moretti et al , 2010; Itzhaki et al , 2011; Matsa et al , 2011; Yazawa et al , 2011; Davis et al , 2012; Egashira et al , 2012; Lahti et al , 2012).”
Induced pluripotent stem cells: at the heart of cardiovascular precision medicine
Chen, I. Y., Matsa, E., & Wu, J. C. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.36 · Cited by 191
Zhang, M., D’Aniello, C., Verkerk, A. O., Wrobel, E., Frank, S., Ward-van Oostwaard, D., Piccini, I., Freund, C., Rao, J., Seebohm, G., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1419553111 · Cited by 175
“This scenario likely has universal validity for nonsense and frame shift lesions in KCNQ1 (10) and contrasts with dominantnegative effects of point mutations causing LQT1 (40, 41).”
BackgroundTanaka, A., Yuasa, S., Mearini, G., Egashira, T., Seki, T., Kodaira, M., Kusumoto, D., Kuroda, Y., Okata, S., Suzuki, T., et al. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.114.001263 · Cited by 160
“independent healthy volunteer and used 2 other, previously characterized, control iPSC lines (controls 2 and 3).(17,18) In HCM patient 1 and controls 1 and 2, iPSCs were generated from skin dermal fibroblasts with retrovirus carrying each of Figure 1.”
MethodSmith, A. S. T., Macadangdang, J. R., Leung, W. W., Laflamme, M. A., & Kim, D. (2016) · Biotechnology Advances · doi:10.1016/j.biotechadv.2016.12.002 · Cited by 169
“…other LQTS subtype disease models, including another LQT1 model by Egashira et al. in which they used MEAs to measure iPSC-CM FPD in response to small molecule inhibitors, thereby demonstrating the role of I Ks de fi ciency in the establishment of the LQT1 phenotype (Egashira et al., 2012).”
Induced Pluripotent Stem Cell–Derived Cardiomyocytes: Boutique Science or Valuable Arrhythmia Model?
Knollmann, B. C. (2013) · Circulation Research · doi:10.1161/circresaha.112.300567 · Cited by 118
“Both LQT1 mutations cause a dominant-negative protein trafficking defect.(3,31) Results of iPSC-CM were confirmed using a heterologous expression system, which makes one wonder whether the use of iPSC-CM was warranted in the first place.”
Garg, P., Garg, V., Shrestha, R., Sanguinetti, M. C., Kamp, T. J., & Wu, J. C. (2018) · Circulation Research · doi:10.1161/circresaha.118.311209 · Cited by 129
Induced pluripotent stem cell-derived cardiomyocytes for drug development and toxicity testing
Sinnecker, D., Laugwitz, K., & Moretti, A. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.03.004 · Cited by 100
Lemoine, M. D., Krause, T., Koivumäki, J. T., Prondzynski, M., Schulze, M. L., Girdauskas, E., Willems, S., Hansen, A., Eschenhagen, T., & Christ, T. (2018) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.117.006035 · Cited by 106
Modelling sarcomeric cardiomyopathies in the dish: from human heart samples to iPSC cardiomyocytes
Eschenhagen, T., Mummery, C., & Knollmann, B. C. (2015) · Cardiovascular Research · doi:10.1093/cvr/cvv017 · Cited by 97
Kussauer, S., David, R., & Lemcke, H. (2019) · Cells · doi:10.3390/cells8111331 · Cited by 101
“1 channel Blocker Prolong FPD in control cells, LQTS cells and control (patient- derived cells) n/a 3D 30-60 days of differentiation +50 days MEA [97]”
BackgroundMethodHuman pluripotent stem cell models of cardiac disease: from mechanisms to therapies
Brandão, K. O., Tabel, V. A., Atsma, D. E., Mummery, C. L., & Davis, R. P. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.030320 · Cited by 104
“Another frameshift mutation inKCNQ1was later shown to cause a similar electrophysiological phenotype and response to adrenergic stimulation in patient hiPSC-CMs (Egashira et al., 2012).”
BackgroundPluripotent Stem Cell Models of Human Heart Disease
Moretti, A., Laugwitz, K.-L., Dorn, T., Sinnecker, D., & Mummery, C. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014027 · Cited by 91
Oikonomopoulos, A., Kitani, T., & Wu, J. C. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.026 · Cited by 94
Parrotta, E. I., Lucchino, V., Scaramuzzino, L., Scalise, S., & Cuda, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124354 · Cited by 88
Suppression-Replacement KCNQ1 Gene Therapy for Type 1 Long QT Syndrome
Dotzler, S. M., Kim, C. S. J., Gendron, W. A. C., Zhou, W., Ye, D., Bos, J. M., Tester, D. J., Barry, M. A., & Ackerman, M. J. (2021) · Circulation · doi:10.1161/circulationaha.120.051836 · Cited by 95
Examining the Paracrine Effects of Exosomes in Cardiovascular Disease and Repair
Gartz, M., & Strande, J. L. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007954 · Cited by 87
Burnett, S. D., Blanchette, A. D., Chiu, W. A., & Rusyn, I. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1894122 · Cited by 116
“meters of iPSC-derived cardiomyocytes [71,87].”
BackgroundInfluentialCasini, S., Verkerk, A. O., & Remme, C. A. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6735-0 · Cited by 83
“These observations are in line with the fact that fatal arrhythmias in LQT1 patients are typically precipitated by increased sympathetic tone and are prevented by beta-blocker therapy.”
BackgroundInfluentialSallam, K., Li, Y., Sager, P. T., Houser, S. R., & Wu, J. C. (2015) · Circulation Research · doi:10.1161/circresaha.116.304494 · Cited by 74
“…↓I Ks current density I Ks activation shifted toward more positive voltages and deactivation being decelerated … … Isoproterenol and propranolol Egashira et al (2012)101 KCNQ1 (p.C1893del) ↓I Ks Prolonged FPD EADs and arrhythmia … E4031, chromanol, isoproterenol, propranolol Wang et al…”
BackgroundHuman Engineered Heart Tissue Models for Disease Modeling and Drug Discovery
Tani, H., & Tohyama, S. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.855763 · Cited by 83
“We also showed that patient-derived iPSCs with amutation inKCNQ1 could recapitulate the disease phenotype in a case of sporadic LQTS1 (Egashira et al., 2012).”
BackgroundHuang, H., Pugsley, M. K., Fermini, B., Curtis, M. J., Koerner, J. E., Accardi, M. V., & Authier, S. (2017) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2017.04.002 · Cited by 78
“, LQTs (Moretti et al., 2010; Itzhaki et al., 2011; Malan et al., 2011; Egashira et al., 2012; Terrenoire et al., 2013), catecholaminergic polymorphic ventricular tachycardia (CPVT) (Yazawa et al.”
BackgroundInfluentialImpaired respiratory function in MELAS‐induced pluripotent stem cells with high heteroplasmy levels
Kodaira, M., Hatakeyama, H., Yuasa, S., Seki, T., Egashira, T., Tohyama, S., Kuroda, Y., Tanaka, A., Okata, S., Hashimoto, H., et al. (2015) · FEBS Open Bio · doi:10.1016/j.fob.2015.03.008 · Cited by 71
“The generation of induced pluripotent stem cells (iPSCs) from patients with genetic disorders holds enormous promise for understanding the pathogenesis of complex diseases [10,11].”
BackgroundMethodSharma, A., Wu, J. C., & Wu, S. M. (2013) · Stem Cell Research & Therapy · doi:10.1186/scrt380 · Cited by 76
Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy
Nicholson, M. W., Ting, C.-Y., Chan, D. Z. H., Cheng, Y.-C., Lee, Y.-C., Hsu, C.-C., Huang, C.-Y., & Hsieh, P. C. H. (2022) · Cells · doi:10.3390/cells11111853 · Cited by 65
“Previous studies using iPSC-derived cardiomyocytes from type-1 LQTS patients revealed that the mutation in KCNQ1 caused potassium ion channel dysfunction resulting in sarcolemmal deficiency [5,6].”
ResultInherited arrhythmias: The cardiac channelopathies
Behere, S. P., & Weindling, S. (2015) · Annals of Pediatric Cardiology · doi:10.4103/0974-2069.164695 · Cited by 73
“This technology has huge potential to aid our understanding of individual channelopathies and further steer the management of channelopathies in an individualistic, genotype-specific manner in the future.[49-51]”
BackgroundHuman Pluripotent Stem Cell-Derived Cardiomyocytes as Research and Therapeutic Tools
Acimovic, I., Vilotic, A., Pesl, M., Lacampagne, A., Dvorak, P., Rotrekl, V., & Meli, A. C. (2014) · BioMed Research International · doi:10.1155/2014/512831 · Cited by 66
Yamagishi, H., Srivastava, D., Keller, B. B., Hs, B., Markwald, R. R., & Nakanishi, T. (2016) · Springer eBooks · doi:10.1007/978-4-431-54628-3 · Cited by 69
van Mil, A., Balk, G. M., Neef, K., Buikema, J. W., Asselbergs, F. W., Wu, S. M., Doevendans, P. A., & Sluijter, J. P. G. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy208 · Cited by 65
“In addition, electrophysiological abnormalities, including a prolonged corrected field potential duration were recorded in LQTS1 iPSC-CMs.(26) Cross-talk between the KCNQ1 mutation and Ca2þ handling abnormalities was reported as well, including the observation that Ca2þ antagonists could rescue the electrophysiologica…”
BackgroundNanopatterned Human iPSC-Based Model of a Dystrophin-Null Cardiomyopathic Phenotype
Macadangdang, J. R., Guan, X., Smith, A. S. T., Lucero, R., Czerniecki, S., Childers, M. K., Mack, D. L., & Kim, D. (2015) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-015-0413-8 · Cited by 65
Paci, M., Hyttinen, J., Rodríguez, B., & Severi, S. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13282 · Cited by 70
“Human-induced pluripotent stem cell-derived cardiomyocytes have already proved their value as in vitro models for investigations into specific pathologies (Moretti et al., 2010; Egashira et al., 2012; Kujala et al., 2012; Terrenoire et al., 2013), and due to their patient-specificity, in identifying drugs for specific”
Human heart disease: lessons from human pluripotent stem cell-derived cardiomyocytes
Giacomelli, E., Mummery, C. L., & Bellin, M. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2546-5 · Cited by 60
Martins, A. M., Vunjak-Novakovic, G., & Reis, R. L. (2014) · Stem Cell Reviews and Reports · doi:10.1007/s12015-013-9487-7 · Cited by 59
“The three most frequently used methods to differentiate human pluripotent stem cells (ES cells and iPS cells) into cardiomyocytes include (please see review in [69]): (1) coculture with mouse visceral endoderm-like (END-2) stromal cells [70–73], (2) spontaneous embryoid body (EB) differentiation in suspension [74–80],…”
BackgroundMethodNozaki, Y., Honda, Y., Tsujimoto, S., Watanabe, H., Kunimatsu, T., & Funabashi, H. (2014) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2014.04.007 · Cited by 52
Embryonic type Na+ channel β-subunit, SCN3B masks the disease phenotype of Brugada syndrome
Okata, S., Yuasa, S., Suzuki, T., Ito, S., Makita, N., Yoshida, T., Li, M., Kurokawa, J., Seki, T., Egashira, T., et al. (2016) · Scientific Reports · doi:10.1038/srep34198 · Cited by 56
Induced Pluripotent Stem Cell-Derived Cardiomyocytes: A Versatile Tool for Arrhythmia Research
Sinnecker, D., Goedel, A., Laugwitz, K., & Moretti, A. (2013) · Circulation Research · doi:10.1161/circresaha.112.268623 · Cited by 56
“Long-QT syndrome type 1 was modeled by reprogramming cells from patients with 2 different mutations of the potassium voltage-gated channel, KQT-like subfamily, member 1 (KCNQ1) gene, R190Q(7) and 1893delC.(8) Both models showed prolonged action potentials attributable to a reduced I Ks current.”
BackgroundPourrier, M., & Fedida, D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020657 · Cited by 56
“In fact, KCNQ1 mutations affecting both trafficking and gating mechanisms of the channel were successfully modeled using this approach [99,100].”
MethodCardiovascular Disease Modeling Using Patient-Specific Induced Pluripotent Stem Cells
Tanaka, A., Yuasa, S., Node, K., & Fukuda, K. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160818894 · Cited by 54
“fibrillation, in order to evaluate the pathological function of the mutation [120].”
BackgroundNew and TALENted Genome Engineering Toolbox
Campbell, J. M., Hartjes, K. A., Nelson, T. J., Xu, X., & Ekker, S. C. (2013) · Circulation Research · doi:10.1161/circresaha.113.301765 · Cited by 53
Current perspectives in genetic cardiovascular disorders: from basic to clinical aspects
Kawashiri, M., Hayashi, K., Konno, T., Fujino, N., Ino, H., & Yamagishi, M. (2013) · Heart and Vessels · doi:10.1007/s00380-013-0391-5 · Cited by 52
“The patient-derived cells showed the electrophysiological properties of the disorder [127, 128].”
BackgroundUesugi, M., Ojima, A., Taniguchi, T., Miyamoto, N., & Sawada, K. (2013) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2013.11.002 · Cited by 51
Zhu, H., Scharnhorst, K. S., Stieg, A. Z., Gimzewski, J. K., Minami, I., Nakatsuji, N., Nakano, H., & Nakano, A. (2017) · Scientific Reports · doi:10.1038/srep43210 · Cited by 53
Induced Pluripotent Stem Cells for the Study of Cardiovascular Disease
Savla, J. J., Nelson, B., Perry, C. N., & ADLER, E. D. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.05.038 · Cited by 48
“Immunohistological testing showed that, in LQTS1 hiPSC-CMs, the diseased KCNQ1 protein localized to the endoplasmic reticulum rather than the cell surface (47,48).”
BackgroundInfluentialDoyle, M. J., Lohr, J. L., Chapman, C. S., Koyano‐Nakagawa, N., Garry, M. G., & Garry, D. J. (2015) · Stem Cell Reviews and Reports · doi:10.1007/s12015-015-9596-6 · Cited by 47
Cardiac disease modeling using induced pluripotent stem cell-derived human cardiomyocytes
Dell’Era, P. (2015) · World Journal of Stem Cells · doi:10.4252/wjsc.v7.i2.329 · Cited by 42
Lei, C. L., Wang, K., Clerx, M., Johnstone, R. H., Hortigon-Vinagre, M. P., Zamora, V., Allan, A., Smith, G. L., Gavaghan, D. J., Mirams, G. R., et al. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00986 · Cited by 40
“In addition, iPSC-CMs can be created with genetic mutations that are presented in inherited cardiovascular diseases such as long QT syndrome (Moretti et al., 2010; Itzhaki et al., 2011; Yazawa et al., 2011; Egashira et al., 2012; Terrenoire et al., 2013), catecholaminergic polymorphic ventricular tachycardia (Fatima e…”
BackgroundKuroda, Y., Yuasa, S., Watanabe, Y., Ito, S., Egashira, T., Seki, T., Hattori, T., Ohno, S., Kodaira, M., Suzuki, T., et al. (2017) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2017.01.002 · Cited by 40
“As controls, we used two populations of iPSCs derived from healthy volunteers, including a previously characterized control iPSC line [20,25,32].”
MethodResultZheng, Z., Wu, Y., Qian, D., & Jiangfang, L. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173813 · Cited by 49
Kiviaho, A., Ahola, A., Larsson, K., Penttinen, K., Swan, H., Pekkanen-Mattila, M., Venäläinen, H., Paavola, K., Hyttinen, J., & Aalto‐Setälä, K. (2015) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2015.04.008 · Cited by 41
“LQTS-specific CMs can be generated and studied in vitro [12–18].”
BackgroundHuman iPSCs and Genome Editing Technologies for Precision Cardiovascular Tissue Engineering
Gähwiler, E. K. N., Motta, S. E., Martin, M., Nugraha, B., Hoerstrup, S. P., & Emmert, M. Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.639699 · Cited by 44
Modeling Inherited Cardiac Disorders: A Cell Is Worth a Thousand Genes
Sallam, K., Kodo, K., & Wu, J. C. (2014) · Circulation Journal · doi:10.1253/circj.cj-14-0182 · Cited by 41
“…to standard pharmacologic agents Force generation abnormalities Novel drug testing LQT1 Moretti et al (2010)16 KCNQ1 (p.R190Q) – + + Egashira et al (2012)37 KCNQ1 (p.C1893del) – + + LQT2 Itzhaki et al (2011)17 KCNH2 (p.A614V) – + + Matsa et al (2011)46 KCNH2 (p.G1681A) – +…”
Takaki, T., Inagaki, A., Chonabayashi, K., Inoue, K., Miki, K., Ohno, S., Makiyama, T., Horie, M., & Yoshida, Y. (2019) · Stem Cells International · doi:10.1155/2019/7532657 · Cited by 36
“Previous papers related to cLQTS patient-specific hiPSC-CMs verified the disease phenotype by using either the manual patch clamp method alone [5, 7] or in combination with the microelectrode array (MEA) system [6, 8].”
Chen, P., Xiao, Y., Wang, Y., Zheng, Z., Chen, L., Yang, X., Li, J., Wu, W., & Zhang, S. (2020) · Theranostics · doi:10.7150/thno.45172 · Cited by 40
“Several research groups have successfully modeled induced pluripotent stem cell-type cardiomyocytes (iPSC-CMs) from patients with many hereditary cardiac ion channel diseases that were different from the well-known subtypes of the long-QT and Brugada syndrome in recent years [3-6].”
BackgroundEmerin plays a crucial role in nuclear invagination and in the nuclear calcium transient
Shimojima, M., Yuasa, S., Motoda, C., Yozu, G., Nagai, T., Ito, S., Lachmann, M., Kashimura, S., Takei, M., Kusumoto, D., et al. (2017) · Scientific Reports · doi:10.1038/srep44312 · Cited by 36
Zhu, W., Bian, X., & Lv, J. (2024) · Heart Rhythm O2 · doi:10.1016/j.hroo.2024.07.006 · Cited by 46
“214 Novel pharmacological agents While b -blockers remain the mainstay of therapy for LQTS, they are not effective in all patients and may have signi fi cant side effects.”
BackgroundInherited heart disease – what can we expect from the second decade of human i PS cell research?
Bellin, M., & Mummery, C. L. (2016) · FEBS Letters · doi:10.1002/1873-3468.12285 · Cited by 33
Ma, D., Liu, Z., Loh, L. J., Zhao, Y., Li, G., Liew, R., Islam, O., Wu, J., Chung, Y. Y., Teo, W. S., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-29574-5 · Cited by 35
Stem cell models as an in vitro model for predictive toxicology
Lynch, S., Pridgeon, C. S., Duckworth, C. A., Sharma, P., Park, B. K., & Goldring, C. E. (2019) · Biochemical Journal · doi:10.1042/bcj20170780 · Cited by 36
Novel Insights into Disease Modeling Using Induced Pluripotent Stem Cells
Egashira, T., Yuasa, S., & Fukuda, K. (2013) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b12-00960 · Cited by 32
Trevisan, M., Sinigaglia, A., Desole, G., Berto, A., Pacenti, M., Palù, G., & Barzon, L. (2015) · Viruses · doi:10.3390/v7072800 · Cited by 28
“For example, several studies used patient-specific iPSC-derived cardiomyocytes to model long QT syndrome and other arrhythmia syndromes and used the cells to rescue the disease phenotype and as platform for drug testing in vitro [27–30].”
Disease modelling using human iPSCs
Chamberlain, S. J. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw209 · Cited by 32
Miller, D. C., Harmer, S. C., Poliandri, A., Nobles, M., Edwards, E. C., Ware, J. S., Sharp, T. V., McKay, T. R., Dunkel, L., Lambiase, P. D., et al. (2017) · Stem Cell Research · doi:10.1016/j.scr.2017.11.003 · Cited by 31
Arrhythmia Mechanisms in Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes
Paci, M., Penttinen, K., Pekkanen-Mattila, M., & Koivumäki, J. T. (2020) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000972 · Cited by 26
Zhu, K., Bao, X., Wang, Y., Lu, T., & Zhang, L. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113970 · Cited by 31
Modeling Long-QT Syndromes with iPS Cells
Sinnecker, D., Goedel, A., Dorn, T., Dirschinger, R. J., Moretti, A., & Laugwitz, K. (2012) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-012-9416-1 · Cited by 27
“[5] LQT1 caused by a P631fs/33 frameshift mutation of the KCNQ1 gene • Extracellular multielectrode recordings • Prolonged action potentials”
BackgroundKuusela, J., Kujala, V. J., Kiviaho, A., Ojala, M., Swan, H., KONTULA, K. K., & Aalto‐Setälä, K. (2016) · SpringerPlus · doi:10.1186/s40064-016-1889-y · Cited by 27
Seki, T., Yuasa, S., Kusumoto, D., Kunitomi, A., Saito, Y., Tohyama, S., Yae, K., Kishino, Y., Okada, M., Hashimoto, H., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085645 · Cited by 24
“The human iPSC line, F16 was generated from human fibroblasts by introducing OCT3/ 4, SOX2, KLF4, and c-MYC with retrovirus vectors [24].”
MethodChristidi, E., Huang, H., & Brunham, L. R. (2018) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2018.06.002 · Cited by 26
New drug discovery of cardiac anti-arrhythmic drugs: insights in animal models
Sharma, A. K., Singh, S., Bhat, M., Gill, K., Zaid, M., Kumar, S., Shakya, A., Tantray, J., Jose, D., Gupta, R., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-41942-4 · Cited by 26
A personalized approach to long QT syndrome
Etheridge, S. P., Asaki, S. Y., & Niu, M. C. (2018) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000587 · Cited by 23
Pan, Z., Ebert, A., & Liang, P. (2020) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-020-02486-y · Cited by 22
“This study also demonstrated deficiency of IKs as part of the LQT1 phenotype and measured the response of patientspecific iPSC-CMs to small molecule inhibitors [23].”
BackgroundKamdar, F. D., Kamdar, A. K., Koyano‐Nakagawa, N., Garry, M. G., & Garry, D. J. (2015) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2015.04.010 · Cited by 22
“[24] Egashira T, Yuasa S, Suzuki T, Aizawa Y, Yamakawa H, Matsuhashi T, et al.”
Young, W. (2012) · Journal of Stem Cell Research & Therapy · doi:10.4172/2157-7633.s10-010 · Cited by 24
“Long QT syndromes KCNQ1 (LQT1); KCNH2 (LQT2), SCN5A (LQT3), CACNA1C (LQT8/ Timothy syndrome) iPSC cardiomyocytes have a prolonged action potential duration reminiscent of delayed repolarization, early afterdepolarization (LQT3), and irregular contraction, excess Ca2+ influx, irregular electrical activity and abnormal…”
BackgroundOvchinnikov, D. A., Hidalgo, A., Yang, S., Zhang, X., Hudson, J. E., Mazzone, S. B., Chen, C., Cooper-White, J. J., & Wolvetang, E. J. (2014) · Stem Cells and Development · doi:10.1089/scd.2014.0195 · Cited by 21
Induced Pluripotency and Gene Editing in Disease Modelling: Perspectives and Challenges
Seah, S., Farran, C. A. E., Warrier, T., Xu, J., & Loh, Y. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161226119 · Cited by 26
“In fact, iPSCs have been utilized as a diagnostic tool in a patient with long QT syndrome caused by a novel mutation [86].”
MethodGélinas, R., Khoury, N. E., Chaix, M., Beauchamp, C., Alikashani, A., Éthier, N., Boucher, G., Villeneuve, L. R., Robb, L. J., Latour, F., et al. (2017) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.117.001755 · Cited by 21
A primer on artificial intelligence for the paediatric cardiologist
Gearhart, A. S., Gaffar, S., & Chang, A. C. (2020) · Cardiology in the Young · doi:10.1017/s1047951120001493 · Cited by 22
“49 Induced pluripotent stem cell-derived cardiomyocytes now effectively capitulate inherited syndromes, such as hypoplastic left heart syndrome, 50 familial hypertrophic cardiomyopathy, 51 long QT syndrome 52 and catecholaminergic polymorphic ventricular tachycardia.”
BackgroundSimons, E., Loeys, B., & Alaerts, M. (2023) · Biomedicines · doi:10.3390/biomedicines11020334 · Cited by 24
Winbo, A., Ramanan, S., Eugster, E., Rydberg, A., Jovinge, S. V., Skinner, J. R., & Montgomery, J. M. (2021) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01002.2020 · Cited by 21
Fan, X., Yang, G., Duru, F., Grilli, M., Akın, İ., Zhou, X., Saguner, A. M., & El‐Battrawy, I. (2023) · Stem Cell Reviews and Reports · doi:10.1007/s12015-023-10615-0 · Cited by 17
Bayzigitov, D. R., Medvedev, S. P., Dementyeva, E. V., Афгановна, Б. С., Pokushalov, E. A., Karaskov, A. M., & Zakian, S. M. (2016) · Cardiology Research and Practice · doi:10.1155/2016/3582380 · Cited by 21
Kuusela, J., Larsson, K., Shah, D. A., Prajapati, C., & Aalto‐Setälä, K. (2017) · Biology Open · doi:10.1242/bio.024216 · Cited by 19
“…tool for the study of inherited cardiac diseases (e.g. LQTS) (Bellin et al., 2013; Moretti et al., 2010; Itzhaki et al., 2011; Lahti et al., 2012; Egashira et al., 2012; MatsaReceived 12 January 2017; Accepted 11 April 2017 1Institute of Biomedical Technology, University of Tampere, Tampere,…”
MethodSong, Y., Zheng, Z., & Lian, J. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.889519 · Cited by 18
Friedrichs, S., Malan, D., & Sasse, P. (2012) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2012.09.006 · Cited by 19
Pilarczyk, G., Raulf, A., Gunkel, M., Fleischmann, B. K., Lemor, R. M., & Hausmann, M. (2016) · Journal of Functional Biomaterials · doi:10.3390/jfb7010001 · Cited by 16
Sogo, T., Morikawa, K., Kurata, Y., Li, P., Ichinose, T., Yuasa, S., Nozaki, D., Miake, J., Ninomiya, H., Shimizu, W., et al. (2016) · Regenerative Therapy · doi:10.1016/j.reth.2015.12.001 · Cited by 17
“Mutations of KCNQ1 to cause LQT1 can reduce IKs and prolong APDs by two mechanisms: 1) impaired trafficking of KCNQ1 proteins to the plasma membrane [7,10], and 2) impaired functions of channel proteins expressed in the membrane [21].”
BackgroundNakao, S., Ihara, D., Hasegawa, K., & Kawamura, T. (2020) · European Cardiology Review · doi:10.15420/ecr.2019.03 · Cited by 17
An in silico hiPSC-Derived Cardiomyocyte Model Built With Genetic Algorithm
Akwaboah, A. D., Tsevi, B., Yamlome, P., Treat, J. A., Brucal-Hallare, M., Cordeiro, J. M., & Deo, M. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.675867 · Cited by 16
“hiPSC-CMs have also been used to better understand drug-induced and inherited cardiac disorders such as long QT syndrome (Moretti et al., 2010; Egashira et al., 2012) and catecholaminergic polymorphic ventricular tachycardia (Fatima et al.”
MethodMultiElec: A MATLAB Based Application for MEA Data Analysis
Georgiadis, V., Stephanou, A., Townsend, P. A., & Jackson, T. (2015) · PLoS ONE · doi:10.1371/journal.pone.0129389 · Cited by 16
Kuusela, J., Kim, J., Räsänen, E., & Aalto‐Setälä, K. (2016) · Stem Cell Reviews and Reports · doi:10.1007/s12015-016-9686-0 · Cited by 17
Luo, Y., Chen, Z., Blanchette, A. D., Zhou, Y., Wright, F. A., Baker, E. S., Chiu, W. A., & Rusyn, I. (2021) · Food and Chemical Toxicology · doi:10.1016/j.fct.2021.111979 · Cited by 15
“Human iPSC-derived cardiomyocytes retain in vivo-relevant phenotypes linked to familial syndromes that result in cardiovascular disease (Egashira et al., 2012; Huang et al., 2011; Itzhaki et al., 2011; Sun et al., 2012).”
Background
Metadata
- Authors
- Egashira, T., Yuasa, S., Suzuki, T., Aizawa, Y., Yamakawa, H., Matsuhashi, T., Ohno, Y., Tohyama, S., Okata, S., Seki, T., Kuroda, Y., Yae, K., Hashimoto, H., Tanaka, T., Hattori, F., Sato, T., Miyoshi, S., Takatsuki, S., Murata, M., Kurokawa, J., Furukawa, T., Makita, N., Aiba, T., Shimizu, W., Horie, M., Kamiya, K., Kodama, I., Ogawa, S., & Fukuda, K.
- Affiliations
- Keio University (JP)
- Tokyo Medical and Dental University (JP)
- Nagasaki University (JP)
- National Cerebral and Cardiovascular Center (JP)
- Shiga University of Medical Science (JP)
- Research Institute of Environmental Medicine, Nagoya University (JP)
- Corresponding author
- Yuasa, Shinsuke
- Fukuda, Keiichi
- ORCID
- Yuasa, Shinsuke
- Suzuki, Tomoyuki
- Aizawa, Yoshiyasu
- Yamakawa, Hiroyuki
- Matsuhashi, Tomohiro
- Ohno, Yohei
- Tohyama, Shugo
- Seki, Tomohisa
- Kuroda, Yusuke
- Yae, Kojiro
- Hashimoto, Hisayuki
- Tanaka, Tomofumi
- Hattori, Fumiyuki
- Sato, Toshiaki
- Takatsuki, Seiji
- Murata, Mitsushige
- Kurokawa, Junko
- Furukawa, Tetsushi
- Makita, Naomasa
- Aiba, Takeshi
- Shimizu, Wataru
- Horie, Minoru
- Ogawa, Satoshi
- Fukuda, Keiichi
- Venue
- Cardiovascular Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-06-27
- Volume
- 95
- Issue
- 4
- Pages
- 419-429
- ISSN
- 0008-6363 (ISSN-L)
- 1755-3245
- OpenAlex
- W2133808555
- Cited by
- 178
- References
- 37
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 9 · 2023: 7 · 2022: 7 · 2021: 16 · 2020: 11 · 2019: 5 · 2018: 12 · 2017: 19 · 2016: 23 · 2015: 29 · 2014: 16 · 2013: 17 · 2012: 5
- FWCI
- 13.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cardiovascular Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (22590779, 22590813, 23590297, 22689027, 24591086, 23790873, 24390199)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion channel regulation and function
- Keywords
- long QT syndrome, induced pluripotent stem cells, iPSC-derived cardiomyocytes, embryoid body differentiation, field potential duration, IKs channel, dominant negative effect, ion channel trafficking, E-4031, chromanol 293B, cardiac arrhythmias, personalized medicine, novel mutations
- MeSH terms
- Action Potentials, Adolescent, Animals, Cell Differentiation, Fluorescent Antibody Technique, Humans, Male, Phenotype, Teratoma, Time Factors, Transfection, Patch-Clamp Techniques, Gene Expression Regulation, Developmental, Coculture Techniques, Genetic Predisposition to Disease, Potassium Channels, Voltage-Gated, Potassium Channel Blockers, Romano-Ward Syndrome, Myocytes, Cardiac, Mice, KCNQ1 Potassium Channel, Intermediate-Conductance Calcium-Activated Potassium Channels, Induced Pluripotent Stem Cells, HEK293 Cells, Embryoid Bodies, Cellular Reprogramming
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.